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DC-SIGN and Langerin are two C-type lectins involved in the initial steps of HIV infections: the
former acts as a viral attachment factor and facilitates viral invasion of the immune system, the latter
has a protective effect. Potential antiviral compounds targeted against DC-SIGN were synthesized
using a common fucosylamide anchor. Their DC-SIGN afﬁnity was tested by SPR and found to be
similar to that of the natural ligand Lewis-X (LeX). The compounds were also found to be selective for
DC-SIGN and to interact only weakly with Langerin. These molecules are potentially useful
therapeutic tools against sexually transmitted HIV infection.
Introduction
Dendritic Cells (DCs) are instrumental in the development
of pathogen-speciﬁc immune responses.1 DCs are professional
antigen-presenting cells that capture microbes entering skin or
mucosal tissues and process them to form MHC-peptide com-
plexes. After antigen uptake, immature DCs acquire the capacity
to migrate to lymph nodes where they present processed antigens
to T-cells, initiating adaptive immune responses. DCs express a
repertoire of pathogen-recognition receptors (PRRs), including
Toll Like Receptors (TLRs) and C-type lectins that mediate
both signaling by self antigens and, in some cases, pathogen
recognition.2 C-type lectins represent a large family of Ca2+
dependent lectins and recognize pathogen-derived carbohydrate
structures. Many different C-type lectins expressed by DCs have
been described,3 including DC-SIGN.
DC-SIGN (DC-Speciﬁc ICAM-3 Grabbing Nonintegrin; CD
209) was originally deﬁned as an intercellular adhesionmolecule-3
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(ICAM-3) receptor that plays an important role in establishing the
ﬁrst contact between DC and resting T cells.4 It is a type II trans-
membrane C-type lectin with a single C-terminal Carbohydrate
Recognition Domain (CRD) within its sequence. In the cellular
membrane, DC-SIGN is assembled as a tetramer, thanks to an
extended coiled-coil region that allows simultaneous presentation
of fourCRDs.5 This oligomerization inﬂuences the lectin avidity in
binding events. DC-SIGN appears to promote dissemination of a
number of viruses (e.g., HIV, hepatitis C virus, Ebola virus)6 and to
participate in suppressing immune responses to some pathogens,
(e.g., Mycobacterium tuberculosis and Helicobacter pylori).7
The various roles attributed to DC-SIGN have generated much
interest towards the identiﬁcation of ligands that can be used
to explore its different functions and/or to inhibit pathogen
binding.8 However, generation of speciﬁc ligands for DC-SIGN
is a challenging task, since many other C-type lectins exist and
share important structural features with DC-SIGN binding site.
Among the list of C-type lectin receptors closely related to DC-
SIGN, Langerin, which is also expressed at the cell surface of
antigen presenting cells, and L-SIGN, expressed on endothelial
liver cell, placenta and lymph nodes, are particularly likely to
interfere with DC-SIGN recognition.9,10 These three lectins are all
calcium-dependent carbohydrate-binding proteins and share the
ability to bind high-mannose oligosaccharides. On the other hand,
the three lectins show different speciﬁcity towards fucosylated
oligosaccharides, a fact which may be used to design DC-SIGN
speciﬁc ligands. Indeed, contrary to L-SIGN, DC-SIGN is known
to bind the Lewis X (LeX) epitope (Galb4[Fuca3]GlcNAc, 1 in
Fig. 1), as illustrated in the recognition mode of Schistosoma
mansoni egg by these lectins.5d,7,11 Moreover, both DC-SIGN and
Langerin appear to recognize blood group B antigen through its
fucose residue12,13 in the primary Ca2+ binding site, but again the
LeX antigen is speciﬁc for DC-SIGN relative to Langerin. As
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Fig. 1 The known fucose-based DC-SIGN ligands 1–3a and the general
structure 4 of the library described in this paper. (IC50 from ref. 14).
shown by X-ray structures,12,13 in addition to binding the fucose
residue on the Ca2+ site, DC-SIGN is uniquely able to stabilize LeX
galactose residue in a second binding area due to key residues that
are absent in Langerin.
The existence of a secondary binding site is also suggested by
a glycan array study of over 100 glycan structures.12 This study
demonstrated that the presence of a terminal fucose residue is not
sufﬁcient for DC-SIGN binding, but 14 fucose-bearing glycans
with the structure of Lewis epitopes were found to bind selectively
to DC-SIGN relative to L-SIGN.
Wehave recently described the ﬁrst fucose-based artiﬁcial ligand
of DC-SIGN (compound 2, Fig. 1), designed to mimic this
trisaccharide.14 The ligand was built by using an a-fucosylamide
anchor to drive the molecule to the DC-SIGN primary binding
site and connecting it to a galactose mimic using a cyclic cis-b-
amino acid ((1S,2R)-2-amino-cyclohexanecarboxylic acid, Fig. 1).
The layout of these residues and more speciﬁcally the linker b-
amino acid allowed the molecule to adopt a three-dimensional
shape similar to the LeX trisaccharide (Fig. 1).15 Amide bonds
were chosen to connect the three elements of ligand 2 to achieve
synthetic simplicity as well as chemical and metabolic stability
of the target molecule. DC-SIGN binding studies performed by
SPR showed that ligand 2 and surprisingly its simpliﬁed version
3a, which does not contain the galactose-mimic moiety, inhibit
DC-SIGN better than the natural ligand 1 (IC50 = 0.35 mM,
0.5 mM and 0.8 mM, respectively).14 The weak difference of
afﬁnity between 2 and 3a, however, suggested that the galactose-
like fragment in 2 gives a limited contribution to the binding
interaction. Building on this knowledge, the goals of the work
we report in this paper were: 1) to establish a minimal structure
easily accessible in large scale and able to engage the receptor
with an afﬁnity similar to that of the natural ligand LeX; 2) to
improve the binding afﬁnity of the fucosylamides by optimizing
the interactions in the secondary binding site. To achieve these
goals, a library of ca. 40 derivatives of general formula 4 was
designed, synthesized and assayed by SPR to determine the ability
of the compounds to inhibit DC-SIGN binding to immobilized
mannosylated Bovine Serum Albumin (Man-BSA). Moreover,
a preliminary selectivity screening was introduced to test some
library members for inhibition of Langerin, using SPR. Selectivity
for DC-SIGN versus Langerin is specially important to develop
inhibitors of sexually transmitted HIV infections. As discussed
above, interaction with DC-SIGN on mucosal DC is used by
the virus to invade the host immune system. On the contrary,
Langerin is suggested to have protective effects against HIV
infection.16 Indeed, some of the fucosylamides examined displayed
an interestingDC-SIGN selectivity and have the potential of being
developed as antiviral agents.
Results and discussion
In order to select reasonable ligand candidates, the properties of
the protein surface in the vicinity of the Ca2+ site in the LewisX-
DC-SIGN complex (1SL5)12 were examined using GRID.17 Both
the DRY probe and the WATER probe were used to identify
hydrophilic and lipophilic regions of the binding site. The molec-
ular representations shown in Fig. 2 were obtained with the
Maestro graphical interface. Various minima for the WATER
probe were identiﬁed in the vicinity of the Ca2+-binding region:
in the crystal structure, they are occupied by crystallographic
water molecules W13, W34 and W36 (Fig. 2a). W13 and W36
are located in two well-deﬁned low interaction energy sites, both
below -11 kcal mol-1. W13 is in the vicinity of the fucose
residue and mediates the interaction of Fuc-O2 with Glu354 and
Lys368, and of Gal-O6 with Asp367 (Fig. 2a). W36 mediates the
interaction of Gal-O4 with Glu358. The W36 site is occupied
by a crystallographic water molecule also in 3 out of 4 known
X-ray structures of DC-SIGN in complex with oligomannosides
(1SL4,12 1K9I,18 2IT519) and it is replaced by one sugar hydroxyl
group in the fourth one (2IT619). The W34 site belongs to a larger
isoenergetic area with a less favorable GRID interaction energy
(ca. -7 kcal mol-1), occupied by water molecules in 2 out of 4
oligomannoside-DC-SIGN complexes (1SL4, 1K9I) and loosely
Fig. 2 Energetic maps of GRID interactions (the Ca2+ ion is shown in yellow) in the structure of the DC-SIGN- LeX complex (pdb code : 1SL5, from
ref. 11). a) WATER probe, -7.0 kcal mol-1 isosurface, showing the binding sites for crystallographic water molecules W13, W34 and W36 in 1SL5. b)
DRY probe, -0.5 kcal mol-1 isosurface, showing hydrophobic areas near the binding region and the groove formed by Phe313 and Leu 371.
This journal is © The Royal Society of Chemistry 2011 Org. Biomol. Chem., 2011, 9, 5778–5786 | 5779
Scheme 1 Retrosynthetic analysis of fucosyl derivative 3.
replaced by mannose hydroxyl groups in the other 2 (2IT5 and
2IT6). In the 1SL5 structure, W34 mediates binding of Gal-O4 to
Ser360 and, together with W36, contributes to the creation of a
secondary binding site involving Leu371, Asp367, Lys373, Glu358
and ﬂanked by Phe313 (Fig. 2a).
GRID analysis with the DRY probe allowed identiﬁcation of
the hydrophobic areas near the binding region, which are shown in
Fig. 2b. Two of them, formed by Val351 and Asn362/Asn344, are
in the immediate vicinity of theCa2+-binding site and establishVan
der Waals contact with the ligand. Phe313 and Leu371/Lys368
side chains form a major hydrophobic groove which ﬂank the
W36 crystallographic site.
Docking of mimic 2 in the 1SL5 structure was obtained using
Glide.20 The complex, which included protein, ligand and the two
water molecules W13 and W36, was prepared with the standard
Preparation Wizard routine of Glide, but the ﬁnal minimization
was performed in implicit (GB/SA21) water with the AMBER*
force ﬁeld. It was found that this procedure allowed achievement
of a better orientation of the water molecules and optimization
of their hydrogen bonding pattern, which in turn avoided steric
clashes in the following re-docking step. Docking obtained with
this model suggested that optimal interaction is reached with
the ligand in an extended conformation, which would allow the
galactose mimic to place two hydroxyl groups in a hydrophilic
patch of the protein near the side chain of Phe313 while nesting
the cyclohexane ring in the groove formed by Phe313 and Leu371
(Fig. 3).
Fig. 3 Docking of mimic 2 in 1SL5. (the Ca2+ ion is shown in yellow).
Based on this model, interesting candidates to replace the
galactose moiety should be molecules able to take advantage
of lipophilic interactions and to interact speciﬁcally with the
secondary hydrophilic regions. Further docking experiments sug-
gested that favorable interactions could also be established by
positively charged groups in the ligands and the negatively charged
regions of the protein created by Asp 367 and Glu 358 side
chains. Following this analysis, candidates for the R group in
4 were selected among commercially available carboxylic acids
featuring aromatic groups and/or hydroxyl groups, amino groups
or acetamides.
The initial set of compounds were synthesized starting from
amine 5,14 which in turn was obtained from tri-O-acetyl-L-
fucosylazide 6 and the protected (1S,2R)-b-amino acid 7, as we
have previously described (Scheme 1).14
The coupling reactions between amine 5 and the acid partners
(RCO2H, Scheme 2) were performed using either HBTU, acid
chloride or EDC/HOBt activation, as described in the Supple-
mentary Information. These conditions afforded the protected
ligands 8 in variable yields (between 43 and 80%) after isolation by
solid phase extraction and chromatographic puriﬁcation.Removal
of the protecting groups under standard Zemplen’s conditions
gave the required compounds 3. If the acid partner carried a Boc
protection, this was ﬁrst removed using a mixture of TFA/CH2Cl2
(1/5). In this way ca. 30 different compounds were prepared (see
Supplementary Information for the structure and characterization
of the entire library). Scheme 2 shows the structure of those that
will be used in the following discussion.
Scheme 2 Coupling reaction of amine 5 with acid partners.
DC-SIGN afﬁnity for the entire set of 30 compounds of general
formula 3 was estimated using a surface plasmon resonance
(SPR) biosensor in a competition assay which we have previously
described.14 The assay allows an afﬁnity evaluation of all ligands
relative to one another on the basis of their percentage inhibition
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Fig. 4 The dependency of DC-SIGN ECD percent activity on concentrations of corresponding compounds. (see original sensorgrams in SI-Fig.4).
of DC-SIGN binding to immobilized mannosylated bovine serum
albumin (Man-BSA). The commercially available Man-BSA used
in these assays contain an average of 12 glycosylation sites
displaying the Mana1-3[Mana1-6]Man branched trisaccharide.
Man-BSA was covalently attached to a carboxymethyl dextran-
functionalized gold SPR sensor chip CM4. Inhibition studies
were then performed using extracellular domain (ECD) of DC-
SIGN (20 mM) injected alone or in the presence of a constant
concentration (300 mM) of the ligands. At this concentration,
for the particular chip used in the assay, LeX exhibited 25%
of inhibition. All the molecules 3 synthesized showed a similar
efﬁciency, independent of the nature of the R group, and none
improved signiﬁcantly over the activity of 3a. To conﬁrm these
data, complete inhibition curves were obtained and IC50 values
were estimated for the selected group of compounds 3a–h shown
in Scheme 2. The results were totally consistent with the previous
observation (Fig. 4).
Interestingly,when ananalogous groupof compounds 9 (Fig. 5),
obtained by reaction of fucosylazide 6 with b-alanine rather than
with 7, was examined in SPR single point assays at 300 mM
concentration, similar inhibition values (25–30%) were obtained.
Thus, these simple a-fucosyl-b-alanyl amides showed a similar
afﬁnity forDC-SIGNas LeX and all the compounds 3 synthesized.
Fig. 5 b-Alanine derivatives 9.
These observations, that are in striking contrast with the
expectations derived from docking studies, strongly suggest that
the R substituent in 3 is not reaching the secondary binding site
identiﬁed by the docking algorithm and may not be interacting
at all with the protein. The unexpected results obtained with a-
fucosyl-b-alanyl amides 9, whilst providing us with very simple
ligands of high efﬁciency,22 conﬁrm that the (1S,2R)-2-amino-
cyclohexanecarboxylic acid scaffold selected for the synthesis of 3
does not enforce optimal interaction of the secondary residue with
the protein. NMR studies are currently in progress to assess the
structural details of the interaction of DC-SIGNwith compounds
3.23 To further explore the role of the b-amino acid structure
in deﬁning ligand–protein interaction, the conﬁguration of the
scaffold was varied systematically and a third set of compounds
was synthesized, where the R fragment was kept unchanged and
the b-conﬁguration was systematically permutated.
The new set of compounds 10–12 (Fig. 6) were synthesized
starting from b-amino acids 13–15 (Fig. 6) using the synthetic
sequence employed for 3 and shown in Schemes 1 and 2. The
syntheses of the enantiomerically pure isomeric amino acids
13–15 and of the corresponding fucosylamide derivatives 10–12
are described in the Supplementary Information. The IC50 ob-
tained by SPR analysis of 10–12 are collected in Fig. 7 and
compared to selected data obtained for 3, for LeX and for L-fucose
(see SI-Fig 5 for original sensorgrams).
The IC50 values obtained for 3a and 3b are consistent with
previous measurements (Fig. 4). The data conﬁrm that the activity
of most fucosylamides is close to that of LeX. The series of
compounds 10a–d show a larger increase of the afﬁnity (a factor
of 3) on passing from the acetamide 10a (R = Me) to the aromatic
amides 10b–d, suggesting a possible role of the aromatic group
in the interaction with the protein. This series, which is built on
the (1R,2S)-2-amino-cyclohexanecarboxylic acid scaffold 13, also
contains the strongest ligands so far, the hydroxybenzoic acid
derivatives 10b and 10c (IC50 470 mM) and is therefore the best
current candidate for further optimization.
To analyze the selectivity properties of the compounds screened,
we developed an additional SPR analysis for Langerin binding
properties. As for DC-SIGN, the ability of Langerin to bind to a
surface functionalized with Man-BSA was tested. In the case of
Langerin, binding to Man-BSA as well as to the dextran matrix
(SI-Fig 1)was observed. Therefore, the dextran/Man-BSA surface
was considered as a combined ligand of Langerin ECD. Upon
titration of the surface with Langerin, a similar saturation curve
than for DC-SIGN was obtained (SI-Fig. 2 and 3). Langerin
displayed an apparent Kd for this surface of 10.3 mM. Indeed,
the two lectins exhibited comparable afﬁnity for this surface, thus
the same ﬁxed concentration of Langerin was used in the SPR-
based competition assay, which allowed a direct comparison of
the binding inhibition properties of the compounds for Langerin
versus DC-SIGN.
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Fig. 6 Library of compounds with different stereochemistry in the cyclohexane scaffold.
Fig. 7 The IC50 values obtained for compounds 10–12 by SPR inhibition assay. IC50 of L-fucose, LeX, 3a and 3b measured in the same conditions are
shown for comparison.
Compounds initially tested for their DC-SIGN inhibitory
potency (Fig. 7) were evaluated with Langerin ECD. The results
are shown in Fig. 8A (see also SI-Fig.6). The inhibitory potency
of the fucosylated mimics is so low against Langerin that it
was not possible to determine an IC50. A crude comparison of
the inhibitors’ properties towards DC-SIGN and Langerin was
obtained by comparing the residual activity of both lectins at the
highest concentration tested for each compound (Fig. 8B).
The data show that many of the fucosylamides tested display a
larger DC-SIGN selectivity than LeX and conﬁrm 10b as one of
the most interesting elements of this group, both for its DC-SIGN
afﬁnity and for its speciﬁcity.
Conclusions
In this paper, we have presented a new library of fucose-based
ligands of DC-SIGN, all characterized by the presence of a b-
amino acid tether and of a fucosylamide anchor, able to direct the
molecules to the DC-SIGN CRD binding site. We were able to
identify many compounds that, compared to the natural ligand
LeX and its previously reported mimic 2, display a similar DC-
SIGN inhibition efﬁciency at a fraction of the synthetic cost.
In particular, a-fucosylamides 9, derived from b-alanine, are
interesting candidates for polyvalent presentations8d–k due to their
high synthetic accessibility and good ligand efﬁciency.22 A second
group of compounds, a-fucosylamides 10 derived from (1R,2S)-
2-amino-cyclohexanecarboxylic acid 13, were also of interest
because they yielded the most active and selective ligand of this
group (10b). Indeed, it may be important that molecules directed
to block the action of DC-SIGN do not interfere with the action
of other lectins. We have recently shown that a-N-fucosylamides
of general formula 3 and 9 interact strongly with the L-fucose
binding lectin PA-IIL of Pseudomonas aeruginosa.24 In particular,
to develop inhibitors of sexually transmittedHIV infections it may
be necessary to select DC-SIGN antagonists that do not interfere
with the action of Langerin. Like DC-SIGN, Langerin is a
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Fig. 8 A) Inhibition of Langerin ECD binding to Man-BSA immobilized on the dextran surface. B) Residual lectin activity at the highest tested
concentration of the ligands (4.6 mM). Langerin, white bars; DC-SIGN, black bars.
membrane C-type lectin known to bind to HIV-1. However, whilst
interaction with DC-SIGN is used by the virus to invade the host
immune system, Langerin is suggested to have protective effects
against HIV infection.16,25 Indeed, Langerhans cells, which are the
ﬁrst dendritic cells to encounterHIV via genitalmucosa, have been
described as a natural barrier for HIV-1 transmission, which is
dependent on Langerin expression.15 The importance of Langerin
in HIV protection has been again emphasized in the context of
HIV-1/Herpes Simplex Virus type II (HSV-2) co-infection.26 In
this last case, it has been demonstrated that HIV susceptibility
of Langerhans cells, and the subsequent virus transmission,
could be promoted by HSV-2-dependent abrogation of Langerin’s
functions. Conversely, DC-SIGN has a well-established role in
dendritic cells-mediatedHIV-1 transmission.6 Thus, the selectivity
of the ligands for DC-SIGN relative to Langerin was also tested.
Indeed, we described here for the ﬁrst time, simultaneous screening
of artiﬁcial compounds towards both lectins. In agreement with
literature data on the natural ligands of these lectins, a low
inhibitory potency of LeX towards Langerin has been observed
in contrast to DC-SIGN. The capacity of LeX and of the other
fucosylated derivatives to inhibit Langerin binding is so low that
we could not perform a full inhibition curve in a reasonable range
of concentration. Therefore, selectivity of the fucose-based ligands
tested was assessed by comparing residual lectin activity at the
highest ligand concentration tested. Most of the a-fucosylamides
assayed were found to be more DC-SIGN selective than the
natural ligand LeX and therefore they are more likely to be turned
into therapeutically useful tools against sexually transmitted HIV
infection.8
Experimental
Langerin and DC-SIGN ECD expression and puriﬁcation
Langerin ECD constructs (comprising residue 68–328) have been
overexpressed using a pET30b derived vector in BL21(DE3) as
described previously.27 The protein was expressed as inclusion
body, refolded and puriﬁed to homogeneity in a functional form
as already described.22 DC-SIGN ECD protein (residue 66–404)
has been overexpressed and puriﬁed as described previously.5a
Surface plasmon resonance analysis
All experiments were performed on a Biacore 3000 using func-
tionalized CM4 sensor chips and the corresponding reagents
from Biacore. Two ﬂow cells were activated as previously
described.28 Flow cell one was then blocked with 30 mL of
1 M ethanolamine and used as a control surface. The sec-
ond one was treated with BSA-Mana1-3[Mana1-6]Man (Man-
BSA, Dextra) (60 mg mL-1) in 10 mM acetate buffer, pH 4.
Remaining activated groups were blocked with 30 mL of 1 M
ethanolamine. The ﬁnal density immobilized on the surface of
the second ﬂow cell was 2000 RU. The Man-BSA used to func-
tionalize CM4 chip harbours 12 glycosylation sites according to
manufacturer.
Two types of SPR tests were set up for the evaluation of
glycomimic compounds. The single point inhibition assay was
used for fast screening of compound selectivity. Here, either DC-
SIGN or Langerin at concentration of 20 mMwere incubated with
corresponding compounds (300 mMﬁnal concentration) and 20 ml
of the samples were co-injected over Man-BSA surface. The lectin
steady state binding responses were extracted from the sensor-
grams and compared with the responses of compound-free lectin
injections and converted to inhibition percent values. In the case of
Langerin inhibition assay, even with parallel functionalization of
the reference surfacewith non-glycosylated BSA, some interaction
of Langerin with the dextran matrix still remains. Indeed, the
dextran/Man-BSA surface has been considered as a combined
ligandofLangerinECD(see Supplementary Information formore
details).
The second type of SPR test was used to estimate the
relative compound afﬁnity to the lectins on the basis of their
IC50 values. This was accomplished in the same manner as in
the single point inhibition assay, except that both lectins were
incubated with increasing concentrations (from 0 to 5000 mM)
of the corresponding compounds, the injected sample volumes
were 13 ml, and the resulting binding responses were con-
verted to residual lectin activity values, which were plotted
against concentration values of the compounds. The relative
IC50 values for each compound were determined by ﬁtting
four parameter logistic model (eqn (1)) to the experimental
data.
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where y is the percent activity, x is the corresponding concentra-
tion, bot and top are the lowest and the highest values of percent
activity, respectively.
In both type of experiments 5 ml ﬂow rate was used and the
running buffer was 25 mM Tris-HCl, pH 8, 150 mM NaCl,
4 mM CaCl2, and 0.005% of P20 surfactant. All the samples were
prepared in the running buffer.
The stability of the surface during a campaign was evaluated
by DC-SIGN ECD binding capacity as a function of the number
of cycles. The chip surfaces demonstrated a strong stability with
negligible decrease of the binding capacity of only 0.06% per cycle
(see data in the Supplementary Information).
Modeling
Grid analysis. The properties of the protein surface in the
vicinity of the Ca2+ site were determined using the protein crystal
structure derived from the complex DC-SIGN-LeX (pdb code
1SL512) and the program GRID17 (version 22). In particular
the DRY probe and the WATER probe were used to identify
hydrophilic and lipophilic regions of the binding site. The accom-
panying program GREAT was used to check the crystal structure
ﬁle and to prepare the ﬁle of coordinates in standard PDB format,
which is used as an input for the program GRIN. This program,
which prepares the input for the main program GRID, was used
to automatically assign atom types and charges for every atom
of the protein, using provided standard parameters. Calculations
of the interaction energy between the probe and each atom of the
proteinwere performed on a box (36.6 A˚ ¥ 23.0 A˚ ¥ 16.6 A˚ per side)
centered on the protein, with a grid spacing of 0.2 A˚ (NPLA = 5)
and its valuewas evaluated at each grid point. A dielectric constant
of 80 was used to simulate a bulk aqueous phase, while a dielectric
constant of 4 was assigned to the interior of the protein.
The output, which consists of an array of interaction energies,
can be visualized as contour surfaces at appropriate energy
levels together with the protein structure. Contours at negative
energy levels delineate regions of attraction between probe and
protein, whereas positive energy levels deﬁne the surface of the
protein. Visual inspection of the contour surfaces superimposed
on the active site of DC-SIGN enabled the identiﬁcation of the
most favored hydrophilic and lipophilic regions, facilitating the
interpretation of protein–ligand interaction.Moreover interaction
energy values between the WATER probe and the protein were
used to identify the important structural water molecules out of
all the crystallized water molecules found in the X-ray structure.
An arbitrary cut-off of -10.42 kcal mol-1 (the most negative
energy value was -14.97 kcal mol-1) was chosen to detect the most
favorable hot spots for a water molecule. This cut off allowed us to
identify two important structural water molecules, corresponding
to W13 and W36 in the crystal structure of DC-SIGN-LeX
complex (1SL5). The DC-SIGN crystal structure including these
twowatermolecules was subsequently used for additional docking
runs.
Docking calculations. Docking calculations were performed
using the program GLIDE 4.5.20 The initial setup for the
receptor preparation before docking runs was performed using
Schro¨dinger’s ‘Protein Preparation Wizard’, starting from the
X-ray crystal structure of the DC-SIGN-LeX complex. All crys-
tallographic water molecules, except for W13 and W36, were
deleted, bond orders assigned and hydrogen atoms added. The
assignments of protonation states for basic and acidic residues
were based on the optimization of hydrogen bonding patterns.
The ﬁnal minimization of the complex was not performed with
the Preparation Wizard default, but the complex was minimized
(500 steps, Truncated Newton Conjugate Gradient method) in
implicit water (GB/SA21 model) using MacroModel29 with the
AMBER* force ﬁeld (dielectric constant 1, cut off extended,
convergence on gradient with threshold of 0.05). The oxygen
atoms of W13 and W36 as well as the Ca2+ ion were an-
chored to the original position through a harmonic potential
during minimization. At the end of the minimization, the root-
mean-square deviation (RMSD) of all heavy atoms was within
0.34 A˚ of the crystallographic positions. Docking calculations
were performed in Standard Precision mode with standard
OPLS-AA(2001)30 force ﬁeld; non-planar conformations of amide
bonds were penalized, Van der Waals radii were scaled by 0.80
and the partial charge cut off was ﬁxed to 0.15. The shape
and properties of the binding site were mapped onto grids with
dimensions of 36 A˚ (enclosing box) and 14 A˚ (ligand diameter
midpoint box), centered on the ligand in the X-ray structure of
the DC-SIGN-LeX complex. Docking was constrained in the Ca2+
binding site by specifying a reference core corresponding to the
C1–C6 carbon andO3–O4–O5 oxygen atoms of the fucose residue
of the reference ligand in the X-ray structure of theDC-SIGN-LeX
complex: ligands that feature the same coremoiety as the reference
ligand are subject to the constraint. The RMSD tolerance for the
position of the core was set to 3.5 A˚. This parameter enforces the
fucosemoiety to be locatedwithin 3.5 A˚ of the fucose residue in the
reference ligand: ligand poses that do notmatch this constraint are
screened out. These constraints allow coordination of the Ca2+ ion
by the hydroxy groups OH-2 and OH-3 of fucose, as observed in
several crystal structure of C-type lectins complexed with fucose-
containing ligands. The RMSD tolerance of 3.5 A˚ was selected
to allow docking poses to explore both possible binding modes
of the vicinal diol. Indeed, crystallographic and NMR data on
DC-SIGN show that the monosaccharide moiety of ligands can
coordinate the Ca2+ ion with the vicinal hydroxyl groups in two
possible orientations, differing by a 180◦ rotation. The quality of
this docking protocol was validated by re-docking the LeX ligand
in the DC-SIGN-LeX complex, which yielded a ligand pose that
could be superimposed with crystalline LeX with RMSD of 1.71 A˚
(0.31 A˚ for the fucose residue).
Synthesis
Solvents were dried by standard procedures: dichloromethane,
methanol, N,N-diisopropylethylamine and triethylamine were
dried over calcium hydride, chloroform and pyridine were dried
over activated molecular sieves. Reactions requiring anhydrous
conditions were performed under nitrogen. 1H, 13C and 31P-
NMR spectra were recorded at 400 MHz on a Bruker AVANCE-
400 instrument. Chemical shifts (d) for 1H and 13C spectra are
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expressed in ppm relative to internal Me4Si as standard. Signals
are abbreviated as s, singlet; bs, broad singlet; d, doublet; t, triplet;
q, quartet; m,multiplet.Mass spectra were obtainedwith a Bruker
ion-trap Esquire 3000 apparatus (ESI ionization) or an Autospec
Fission Instrument (FAB ionization). HRMS (FT-ICR, ESI) were
obtained with an Apex II instrument. Thin layer chromatography
(TLC) was carried out with pre-coated Merck F254 silica gel plates.
Flash chromatography (FC) was carried out with Macherey-
Nagel silica gel 60 (230–400 mesh). The libraries were synthesized
through the common approach shown in Scheme 1.14 All synthetic
schemes and procedures, the synthesis and characterization of new
intermediates, the synthesis and characterization of the full library
of ligands (3, 9, 11 and 12) as well as their 1H- and 13C-NMR
spectra are collected in the Supplementary Information. Below we
report the characterization of compounds 10a–d (from (1R,2S)-
2-aminocyclohexanecarboxylic acid). Compounds 3a and 5 were
previously described.14
N-((1R,2S)-2-Acetamido-cyclohexanecarboxyl)-a-L-fucopyrano-
sylamine (10a)
The crude hydrogenation product of 28 (see Supplementary
Information–SI-Scheme 3) was used in the general acetylation
method (see Supplementary Information). The product was puri-
ﬁed by ﬂash chromatography on silica gel (AcOEt, Rf 0.29). Yield:
27 mg (82%). Zemplen deprotection and ﬂash chromatography
(85 : 15 CHCl3 :MeOH, Rf 0.18) afforded 10a. Yield: 13 mg (65%).
1H-NMR (400 MHz, CD3OD): d (ppm) = 1.18 (d, 3H, J5-6 =
6.5 Hz, HF6), 1.32–1.50 (m, 2H, HCy4ax and HCy5ax), 1.55 –1.68 (m,
3H, HCy6ax, HC3ax and HC4eq or HC5eq), 1.73–1.78 (m, 1H, HCy4eq or
HCy5eq), 1.83–1.92 (m, 1H, HCy3eq and HC6eq), 1.94 (s, 3H, Ac-Me),
2.71–2.75 (m, 1H, HCy1), 3.63–3.66 (m, 1H, HF4), 3.74 (dd, J3-4 =
3.3 Hz, J3-2 = 10.3 Hz, 1H, HF3), 3.79 (q, J5-6 = 6.5 Hz, 1H, HF5),
3.94 (dd, J1-2 = 5.6 Hz, J2-3 = 10.2 Hz, 1H, HF2), 4.18–4.25 (m,
1H, HCy2), 5.51 (d, 1H, J1-2 = 5.6 Hz, HF1). 13C-NMR (100 MHz,
CD3OD): d (ppm) = 17.0 (CF6), 23.0 (Ac-Me), 23.6 (CCy4 or CCy5),
24.2 (CCy4 or CCy5), 26.8 (CCy6), 30.7 (CCy3), 40.3 (CCy1), 46.4 (CCy2),
68.3 (CF2), 68.8 (CF5), 71.8 (CF3), 73.3 (CF4), 78.3 (CF1), 173.1
(NHCO), 177.5 (NHCO). HRMS (FT-ICR, ESI): m/z calcd for
C15H26N2O6: 353.16831 [M + Na]+; found: 353.16838. [a]D -77.5
(c 0.35, EtOH)
N-[(1R,2S)-2-(3-Hydroxybenzamido)cyclohexanecarboxyl]-a-L-
fucopyranosylamine (10b)
The crude hydrogenation product of 28 (see Supplementary
Information–SI-Scheme 3) was coupled with 3-hydroxybenzoic
acid using the HBTU general procedure (see Supplementary
Information) and the product was puriﬁed by ﬂash chromatog-
raphy (6 : 4 AcOEt : petroleum ether, Rf 0.38). Yield: 13 mg
(31%). Zemplen deprotection and ﬂash chromatography (85 : 15
chloroform :methanol, Rf 0.17) afforded 10b. Yield: 8 mg (89%).
1H-NMR(400MHz,CD3OD): d (ppm)= 1.18 (d, 3H, J5-6 = 6.5Hz,
HF6), 1.42–1.55 (m, 2H,HCy4ax andHCy5ax), 1.61–1.76 (m, 4H,HCy6ax,
HCy3ax, HCy4eq and HCy5eq), 1.94–2.02 (m, 1H, HCy6eq), 2.16–2.24 (m,
1H, HCy3eq), 2.86–2.91 (m, 1H, HCy1), 3.63–3.66 (m, 1H, HF4), 3.74–
3.80 (m, 2H, HF5 and HF3), 3.91–3.95 (m, 1H, HF2), 4.28–4.33 (m,
1H,HCy2), 5.52–5.54 (m, 1H,HF1) 6.90–6.95 (m, 1H,Ar), 7.18–7.28
(m, 3H, Ar). 13C-NMR (100MHz, CD3OD): d (ppm) = 17.0 (CF6),
23.8 (CCy4 or CCy5), 24.2 (CCy4 or CCy5), 27.8 (CCy6), 30.4 (CCy3), 46.2
(CCy1), 50.2 (CCy2), 68.2 (CF2), 68.8 (CF5), 71.7 (CF3), 73.3 (CF4),
78.4 (CF1), 115.3 (Ar), 119.4 (Ar), 119.7 (Ar), 130.8 (Ar), 137.5
(Cquart.Ar.), 158.9 (Cquart.Ar.), 170.0 (NHCO), 178.0 (NHCO). HRMS
(FT-ICR, ESI): m/z calcd for C20H28N2O7: 431.17887 [M + Na]+;
found: 431.17948. [a]D -53.1 (c 0.25, MeOH)
N-[(1R,2S)-2-(3,5-Dihydroxybenzamido)cyclohexanecarboxyl]-a-
L-fucopyranosylamine (10c)
The crude hydrogenation product of 28 (see Supple-
mentary Information–SI-Scheme 3) was coupled with 3,5-
dihydroxybenzoic acid using the HBTU general procedure (see
Supplementary Information) and the product was puriﬁed by
ﬂash chromatography (7 : 3 ethyl acetate : n-hexane,Rf 0.43).Yield:
17 mg (37%). Zemplen deprotection and ﬂash chromatography
(85 : 15 chloroform :methanol, Rf 0.14) afforded 10c. Yield: 10 mg
(91%). 1H-NMR (400 MHz, CD3OD): d (ppm) = 1.19 (d, 3H,
J5-6 = 6.5 Hz, HF6), 1.42–1.55 (m, 2H, HCy4ax and HCy5ax), 1.61–1.73
(m, 4H, HC6ax, HCy3ax, HCy4eq and HCyeq), 1.92–2.02 (m, 1H, HCy6eq),
2.16–2.22 (m, 1H, HCy3eq), 2.85–2.90 (m, 1H, HCy1), 3.64–3.66 (m,
1H, HF4), 3.77 (dd, J3-4 = 3.3 Hz, J2-3 = 10.3 Hz, 1H, HF3), 3.79
(q, J5-6 = 6.5 Hz, 1H, HF5), 3.95 (dd, 1H, J1-2 = 5.6 Hz, J2-3 =
10.3 Hz, HF2), 4.25–4.30 (m, 1H, HCy2), 5.55 (d, 1H, J1-2 = 5.6 Hz,
HF1) 6.39 (bs, 1H, Ar), 6.68 (bs, 2H, Ar). 13C-NMR (100 MHz,
CD3OD): d (ppm) = 17.0 (CF6), 23.8 (CCy4 or CCy5), 24.1 (CCy4 or
CCy5), 27.9 (CCy6), 30.4 (CCy3), 46.2 (CCy1), 50.2 (CCy2), 68.2 (CF2),
68.8 (CF3 or CF5), 71.7 (CF3 or CF5), 73.3 (CF4), 78.4 (CF1), 106.8
(Ar), 106.8 (Ar), 138.1 (Cquart., Ar.), 160.0 (Cquart., Ar.), 170.0
(NHCO), 178.0 (NHCO). HRMS (FT-ICR, ESI): m/z calcd for
C20H28N2O8: 447.17379 [M + Na]+; found: 447.17407. [a]D -65.7
(c 0.20, MeOH)
N-[(1R,2S)-2-(3-Pyridinecarboxamido)cyclohexanecarboxyl]-a-
L-fucopyranosylamine (10d)
The crude hydrogenation product of 28 (see Supplementary
Information–SI-Scheme 3) was coupled with nicotinic acid us-
ing the HBTU general procedure (see Supplementary Infor-
mation) and the product was puriﬁed by ﬂash chromatogra-
phy (97 : 3 ethyl acetate : triethyl amine, Rf 0.17). Yield: 19 mg
(50%) Zemplen deprotection and ﬂash chromatography (85 : 15
chloroform :methanol, Rf 0.17) afforded 10d. Yield: 6 mg (43%).
1H-NMR(400MHz,CD3OD): d (ppm)= 1.19 (d, 3H, J5-6 = 6.5Hz,
HF6), 1.43–1.55 (m, 2H,HCy4ax andHCy5ax), 1.67–1.78 (m, 4H,HCy6ax,
HCy3ax, HCy4eq and HC5eq), 1.94–2.04 (m, 1H, HCy3eq), 2.14–2.21 (m,
1H, HCy6eq), 2.88–2.92 (m, 1H, HCy1), 3.63–3.66 (m, 1H, HF4), 3.74
(dd, J3-4 = 3.4 Hz, J2-3 = 10.3 Hz, 1H, HF3), 3.78 (q, J5-6 = 6.5 Hz,
1H,HF5), 3.93 (dd, 1H, J1-2 = 5.6Hz, J2-3 = 10.2Hz, HF2), 4.37–4.42
(m, 1H, HCy2), 5.53 (d, 1H, J1-2 = 5.6 Hz, HF1), 7.50–7.53 (m, 1H,
HAr5), 8.20 (d, 1H, JAr5-JAr6 = 8.0 Hz, HAr6), 8.65 (d, 1H, JAr4-JAr5 =
4.5 Hz, HAr4), 8.92 (s, 1H, HAr2). 13C-NMR (100 MHz, CD3OD):
d (ppm) = 17.0 (CF6), 23.7 (CCy4 and CCy5), 24.1 (CCy3), 27.4 (CCy6),
30.4 (CCy1), 50.4 (CCy2), 68.2 (CF2), 68.8 (CF5), 71.7 (CF3), 73.3 (CF4),
78.3 (CF1), 125.1 (CAr5), 132.7 (Cquart.Ar), 137.4 (CAr6), 149.5 (CAr2),
152.5 (CAr4), 167.95 (NHCO), 177.76 (NHCO). HRMS (FT-ICR,
ESI): m/z calcd for C19H27N3O6: 416.17921 [M + Na]+; found:
416.17934. [a]D -81.9 (c 0.15, MeOH)
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